You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 125 No. 4, April 2007 TABLE OF CONTENTS
  Archives
  •  Online Features
  Commentary
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Citing articles on Web of Science (2)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Aging/ Geriatrics
 •Macular Degeneration
 •Drug Therapy
 •Drug Therapy, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Bevacizumab vs Ranibizumab Treatment for Age-Related Macular Degeneration

A Head-to-Head Comparison Is Needed

Arch Ophthalmol. 2007;125(4):557-558.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

New England Journal of Medicine

Ranibizumab for Neovascular Age-Related Macular Degeneration 

Philip J. Rosenfeld, MD, PhD, David M. Brown, MD, Jeffrey S. Heier, MD, David S. Boyer, MD, Peter K. Kaiser, MD, Carol Y. Chung, PhD, Robert Y. Kim, MD, for the MARINA Study Group.

Background:  Ranibizumab—a recombinant, humanized, monoclonal antibody Fab that neutralizes all active forms of vascular endothelial growth factor A—has been evaluated for the treatment of neovascular age-related macular degeneration.

Methods:  In this multicenter, 2-year, double-blind, sham-controlled study, we randomly assigned patients with age-related macular degeneration with either minimally classic or occult (with no classic lesions) choroidal neovascularization to receive 24 monthly intravitreal injections of ranibizumab (either 0.3 mg or 0.5 mg) or sham injections. The primary end point was the proportion of patients losing fewer than 15 letters from baseline visual acuity at 12 months.

Results:  We enrolled 716 patients in the study. At 12 months, . . . [Full Text of this Article]


AUTHOR INFORMATION
Lee M. Jampol, MD



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Ranibizumab for neovascular age-related macular degeneration
Hernandez-Pastor et al.
Am J Health Syst Pharm 2008;65:1805-1814.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2007 American Medical Association. All Rights Reserved.